2025 Q4 -tulosraportti
69 päivää sitten
‧39 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | NON | NON | ||
| 400 | NON | NON | ||
| 200 | NON | NON | ||
| 217 | SSWM | NON | ||
| 20 | AVA | SSWM |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13 t sittenSO we have solid support at 13.5 with ~76k shares and now 10k at 14.25 + Steadily increasing selling activity... @Sweetspot - You possibly nailed the bullseye with your latest theory that Penwater has finished divesting their shares. Has the time to fly north started, now that essential news is just around the corner?
·40 min sitten · MuokattuYes, it could well seem that Penwater is about to finish selling,- let's just wait and see the next 2-4 trading days. The absolutely essential and crucial news comes in Q2 (Read-out on Phase I in uTREAT) most realistically is ult. Q2, as Final results come in H2. According to communication currently. We have a couple of modest 'snacks' before: May 28: Q1 - should be a non-event in the form of "everything is going according to plan - we have not observed any surprises and we cannot say more at the present time" - which is excellent news! May 30 - June 2: The SNMMI conference - interesting, they will probably present a bit more here, but nothing decisive. An abstract should apparently come mid-May!? We'll have to follow up on that and see what it says. June 8-9: ACROBATIC - currently cannot see if they will participate, but it seems likely.
·1 päivä sittenI think we found our support 😅 Wow, that's a lot!!!
·2 päivää sittenA stock I don't dare to sell, but oh my, how sad it is to see it trickle down every day 🥲 is now down to a 15% return- ·1.5.Curasight is mentioned along with some of the big players in the class. https://www.fortunebusinessinsights.com/de/markt-f-r-glioblastom-medikamente-116045
·1.5.I have owned shares in both Curasight and fluoguide from the very beginning and one must say that they have things in common..Without playing "too" smart within the medical world, what is truly valuable in these two companies (with the same founder Andreas Kjær) is the receptor.. The one that makes cancer visible during scanning and the one that allows the radioactive substance to find its way right into the diseased area.. And fluoguide is the same receptor that makes the cancer light up.. Throughout the many years I have owned these two shares, I have just become more and more confident and I definitely think the management is fantastic. They take their time to do things properly. The management holds large shareholdings, which means they want the same as all of us shareholders.. In fact, I believe they have never disappointed/failed.. Not even during previous capital increases... So far, I think they have fulfilled all my hopes and expectations...And with the phrase ..What we can see - that we can also treat..... And what is meant by that ...is that what has already been shown to work in utrace.. will also work in utread.. I don't want to hype these 2 shares with this text.. In reality, I just want to say.. Are we really aware of how much potential this share has.. When I look at trades, it doesn't always seem like people are aware of it.. It might be acquired this year and for 10x ..15x..20x.. I don't know.. I myself own a large number of shares in both Curasight and fluoguide.. There isn't much new in what I'm writing. It's perhaps aimed a bit at passers-by.. And as always ..please add comments or any corrections to what I write regards
·1.5.It is indeed enormous what they both possess, however, it seems cura is further along than fluen, as fluen has delayed their product launch for 3 years now, which I am not satisfied with regarding fluen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
69 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenSO we have solid support at 13.5 with ~76k shares and now 10k at 14.25 + Steadily increasing selling activity... @Sweetspot - You possibly nailed the bullseye with your latest theory that Penwater has finished divesting their shares. Has the time to fly north started, now that essential news is just around the corner?·40 min sitten · MuokattuYes, it could well seem that Penwater is about to finish selling,- let's just wait and see the next 2-4 trading days. The absolutely essential and crucial news comes in Q2 (Read-out on Phase I in uTREAT) most realistically is ult. Q2, as Final results come in H2. According to communication currently. We have a couple of modest 'snacks' before: May 28: Q1 - should be a non-event in the form of "everything is going according to plan - we have not observed any surprises and we cannot say more at the present time" - which is excellent news! May 30 - June 2: The SNMMI conference - interesting, they will probably present a bit more here, but nothing decisive. An abstract should apparently come mid-May!? We'll have to follow up on that and see what it says. June 8-9: ACROBATIC - currently cannot see if they will participate, but it seems likely.
- ·1 päivä sittenI think we found our support 😅 Wow, that's a lot!!!
- ·2 päivää sittenA stock I don't dare to sell, but oh my, how sad it is to see it trickle down every day 🥲 is now down to a 15% return
- ·1.5.Curasight is mentioned along with some of the big players in the class. https://www.fortunebusinessinsights.com/de/markt-f-r-glioblastom-medikamente-116045
- ·1.5.I have owned shares in both Curasight and fluoguide from the very beginning and one must say that they have things in common..Without playing "too" smart within the medical world, what is truly valuable in these two companies (with the same founder Andreas Kjær) is the receptor.. The one that makes cancer visible during scanning and the one that allows the radioactive substance to find its way right into the diseased area.. And fluoguide is the same receptor that makes the cancer light up.. Throughout the many years I have owned these two shares, I have just become more and more confident and I definitely think the management is fantastic. They take their time to do things properly. The management holds large shareholdings, which means they want the same as all of us shareholders.. In fact, I believe they have never disappointed/failed.. Not even during previous capital increases... So far, I think they have fulfilled all my hopes and expectations...And with the phrase ..What we can see - that we can also treat..... And what is meant by that ...is that what has already been shown to work in utrace.. will also work in utread.. I don't want to hype these 2 shares with this text.. In reality, I just want to say.. Are we really aware of how much potential this share has.. When I look at trades, it doesn't always seem like people are aware of it.. It might be acquired this year and for 10x ..15x..20x.. I don't know.. I myself own a large number of shares in both Curasight and fluoguide.. There isn't much new in what I'm writing. It's perhaps aimed a bit at passers-by.. And as always ..please add comments or any corrections to what I write regards·1.5.It is indeed enormous what they both possess, however, it seems cura is further along than fluen, as fluen has delayed their product launch for 3 years now, which I am not satisfied with regarding fluen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | NON | NON | ||
| 400 | NON | NON | ||
| 200 | NON | NON | ||
| 217 | SSWM | NON | ||
| 20 | AVA | SSWM |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
69 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenSO we have solid support at 13.5 with ~76k shares and now 10k at 14.25 + Steadily increasing selling activity... @Sweetspot - You possibly nailed the bullseye with your latest theory that Penwater has finished divesting their shares. Has the time to fly north started, now that essential news is just around the corner?·40 min sitten · MuokattuYes, it could well seem that Penwater is about to finish selling,- let's just wait and see the next 2-4 trading days. The absolutely essential and crucial news comes in Q2 (Read-out on Phase I in uTREAT) most realistically is ult. Q2, as Final results come in H2. According to communication currently. We have a couple of modest 'snacks' before: May 28: Q1 - should be a non-event in the form of "everything is going according to plan - we have not observed any surprises and we cannot say more at the present time" - which is excellent news! May 30 - June 2: The SNMMI conference - interesting, they will probably present a bit more here, but nothing decisive. An abstract should apparently come mid-May!? We'll have to follow up on that and see what it says. June 8-9: ACROBATIC - currently cannot see if they will participate, but it seems likely.
- ·1 päivä sittenI think we found our support 😅 Wow, that's a lot!!!
- ·2 päivää sittenA stock I don't dare to sell, but oh my, how sad it is to see it trickle down every day 🥲 is now down to a 15% return
- ·1.5.Curasight is mentioned along with some of the big players in the class. https://www.fortunebusinessinsights.com/de/markt-f-r-glioblastom-medikamente-116045
- ·1.5.I have owned shares in both Curasight and fluoguide from the very beginning and one must say that they have things in common..Without playing "too" smart within the medical world, what is truly valuable in these two companies (with the same founder Andreas Kjær) is the receptor.. The one that makes cancer visible during scanning and the one that allows the radioactive substance to find its way right into the diseased area.. And fluoguide is the same receptor that makes the cancer light up.. Throughout the many years I have owned these two shares, I have just become more and more confident and I definitely think the management is fantastic. They take their time to do things properly. The management holds large shareholdings, which means they want the same as all of us shareholders.. In fact, I believe they have never disappointed/failed.. Not even during previous capital increases... So far, I think they have fulfilled all my hopes and expectations...And with the phrase ..What we can see - that we can also treat..... And what is meant by that ...is that what has already been shown to work in utrace.. will also work in utread.. I don't want to hype these 2 shares with this text.. In reality, I just want to say.. Are we really aware of how much potential this share has.. When I look at trades, it doesn't always seem like people are aware of it.. It might be acquired this year and for 10x ..15x..20x.. I don't know.. I myself own a large number of shares in both Curasight and fluoguide.. There isn't much new in what I'm writing. It's perhaps aimed a bit at passers-by.. And as always ..please add comments or any corrections to what I write regards·1.5.It is indeed enormous what they both possess, however, it seems cura is further along than fluen, as fluen has delayed their product launch for 3 years now, which I am not satisfied with regarding fluen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | NON | NON | ||
| 400 | NON | NON | ||
| 200 | NON | NON | ||
| 217 | SSWM | NON | ||
| 20 | AVA | SSWM |
Välittäjätilasto
Dataa ei löytynyt